Skip to main content
Log in

Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions

  • Original article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript



Hypertension is a significant risk factor in heart failure for worldwide patients. More than half of hypertensive patients suffer from heart failure. Recently, sacubitril/valsartan (sac/val) has been approved as an antihypertensive agent in China and Japan. Additionally, it is not approved for treating hypertension in Europe or the USA.


To accumulate more real-world experiences to investigate the effectiveness and optimize clinical medication of sac/val in hypertensive patients with heart failure.


We retrospectively enrolled adult patients diagnosed with hypertension (HTN) and heart failure (HF) and newly treated with sac/val. The baseline characteristics and clinical outcomes were retrospectively extracted from electronic medical records (EMR) in three centers. The efficacy and safety of sac/val were first analyzed in all enrolled patients. Stratified analyses were conducted in patients with different ages (≥ 65, < 65), maximum tolerated doses (≥ 200 mg/days, < 200 mg/days), and renal functions (e-GFR ≥ 60 ml/min/1.73 m2, < 60 ml/min/1.73 m2).


Overall, 794 patients diagnosed with both HF and HTN were included in our study. During follow-up, significant reductions were found in blood pressure (BP) (SBP 12.8 ± 21.2 mmHg, P < 0.001, DBP 7.1 ± 16.5 mmHg, P < 0.001), and cardiac biomarkers (cardiac troponin 1.78 ± 19.1 ng/mL, P < 0.001, NT-proBNP 1403 ± 6937 pg/mL, P < 0.001) from baseline. In stratification analyses, the lower dosage group earned a higher BP control rate (83.4% vs. 75.6%, P = 0.025) and an overall improvement rate of cardiac indicators (61.3% vs. 48.0%, P = 0.002). The younger patients’ group had significantly less cumulative hazard of recurrent cerebral-cardiovascular events than the elder group (log-rank P value < 0.001). Patients with renal dysfunction were observed with more AE incidences.


Sac/val could reduce BP and improve cardiac structural and functional parameters in hypertensive patients with HF, even with less than target doses. However, more attention should be paid to older patients and renal dysfunction patients when using sac/val because of additional risks in adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others


  1. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of Disease 2000. Part 1: estimates of blood pressure levels. J Hypertens. 2006;24(3):413–22.

    Article  CAS  PubMed  Google Scholar 

  2. Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with Essential Hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  3. Park JB, Kario K, Wang JG. Systolic Hypertension: an increasing clinical challenge in Asia. Hypertens Res. 2015;38(4):227–36.

    Article  PubMed  Google Scholar 

  4. Guideline for the. Pharmacological treatment of Hypertension in adults. Geneva: World Health Organization; 2021.

    Google Scholar 

  5. Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice. Guideline for primary care of Hypertension (2019). Chin J Gen Pract. 2019;18(4):301–13.

    Article  Google Scholar 

  6. Zhang J, Zhang Y. China heart failure registry study—a multicenter, prospective investigation for preliminary analysis on etiology, clinical features and treatment in heart failure patients. Chin Circulation J. 2015;30(5):413–6.

    Article  Google Scholar 

  7. Katsi V, Skalis G, Pavlidis AN, Makris T, Nihoyannopoulos P, Tousoulis D, Kallikazaros I. Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial Hypertension? Eur Heart J Cardiovasc Pharmacother. 2015;1(4):260–4.

    Article  CAS  PubMed  Google Scholar 

  8. Eadie AL, Brunt KR, Herder M. Exploring the food and drug administration’s review and approval of entresto (sacubitril/valsartan). Pharmacol Res Perspect. 2021;9(3):e00794.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S, Senni M. Real-world effectiveness and safety of sacubitril/valsartan in Heart Failure: a systematic review. Int J Cardiol. 2021;331:164–71.

    Article  PubMed  Google Scholar 

  10. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66.

    Article  CAS  PubMed  Google Scholar 

  11. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with Hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.

    Article  CAS  PubMed  Google Scholar 

  12. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004.

    Article  CAS  PubMed  Google Scholar 

  13. Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank K, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE, Authors/Task Force Members. 2023 ESH guidelines for the management of arterial Hypertension the task force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023.

    Article  Google Scholar 

  14. Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O’Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators. Echocardiographic features of patients with Heart Failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74(23):2858–73.

    Article  CAS  PubMed  Google Scholar 

  15. Di Lenarda A, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, Bilato C, Passantino A, Carluccio E, Villani A, Degli Esposti L, d’Agostino C, Peruzzi E, Poli S, Iacoviello M. Sacubitril/Valsartan in Heart Failure with reduced ejection fraction: real-world experience from Italy (the REAL.IT Study). J Clin Med. 2023;12(2): 699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhang H, Huang T, Shen W, Xu X, Yang P, Zhu D, Fang H, Wan H, Wu T, Wu Y, Wu Q. Efficacy and safety of sacubitril-valsartan in Heart Failure: a meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7(6):3841–50.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chua SK, Lai WT, Chen LC, Hung HF. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and Meta-analysis of randomized controlled trials. J Clin Med. 2021;10(13): 2824.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kario K. The Sacubitril/Valsartan, a first-in-Class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in Hypertension, Heart Failure, and Beyond. Curr Cardiol Rep. 2018;20(1):5.

    Article  PubMed  Google Scholar 

  19. Houchen E, Loefroth E, Schlienger R, Proudfoot C, Corda S, Saha S, Satwase SK, Studer R. Hospitalization rates in patients with Heart Failure and reduced ejection fraction initiating sacubitril/valsartan or angiotensin-converting enzyme Inhibitors/angiotensin receptor blockers: a retrospective cohort study. Cardiol Ther. 2022;11(1):113–27.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (prospective comparison of angiotensin receptor Neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circ Heart Fail. 2018;11(4): e004745.

    Article  CAS  PubMed  Google Scholar 

  21. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD. Prospective comparison of ARNI with ACEI to Determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) investigators. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in Heart Failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228–34.

    Article  CAS  PubMed  Google Scholar 

  22. General Practitioner Branch of Chinese Medical Doctor Association. Chinese expert consensus on clinical use of sacubitril/valsartan for cardiovascular diseases in primary care. Chin Gen Pract. 2021;24(23):2885–90.

    Google Scholar 

  23. Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. World J Cardiol. 2012;4(5):135–47.

    Article  PubMed  PubMed Central  Google Scholar 

  24. To TL, Doan TN, Ho WC, Liao WC. Prevalence of frailty among community-dwelling older adults in asian countries: a systematic review and meta-analysis. Healthc (Basel). 2022;10(5): 895.

    Article  Google Scholar 

  25. Li X, Zuo C, Chen C, Tian D, Li J, Fan L, Li X, Lv Q. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: a prospective cohort study. Int J Cardiol. 2023;371:244–51.

    Article  PubMed  Google Scholar 

  26. Bahat G, İlhan B, Tufan A, Kılıç C, Karan MA, Petrovic M. Hypotension under antihypertensive treatment and Incident hospitalizations of nursing home residents. Drugs Aging. 2022;39(6):477–84.

    Article  CAS  PubMed  Google Scholar 

  27. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–69.

    Article  PubMed  Google Scholar 

  28. Spannella F, Marini M, Giulietti F, Rosettani G, Francioni M, Perna GP, Sarzani R. Renal effects of sacubitril/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019;14(8):1287–97.

    Article  PubMed  PubMed Central  Google Scholar 

  29. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in Heart Failure. N Engl J Med. 2014;371(11):993–1004.

    Article  CAS  PubMed  Google Scholar 

  30. Wessler BS, Kramer DG, Kelly JL, Trikalinos TA, Kent DM, Konstam MA, Udelson JE. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail. 2011;4(5):578–88.

    Article  CAS  PubMed  Google Scholar 

  31. Savarese G, Musella F, D’Amore C, Vassallo E, Losco T, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail. 2014;2(2):148–58.

    Article  PubMed  Google Scholar 

Download references


The authors would like to thank Jinyuan Zhang, Fei Gao (Beijing Medicinovo Technology Co., Ltd., Beijing, China), and Ze Yu (Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China) for their technical assistance.

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Xiaoyu Li, Qianzhou Lv or Xiaolan Bian.

Ethics declarations

Ethics Approval

This study involving human participants was reviewed and approved by the Research Ethics Commission of Ruijin Hospital (KY 2022–154). The Research Ethics Committee approved the study protocol and waived the informed consent because of the retrospective nature of this study.


This work was supported by Clinical comprehensive evaluation and treatment management pathway of sav/val in the real world of hypertension. Grant/Award Number: SHYXHZP-2021-002.

Conflict of Interest

The authors have no relevant financial or non-financial interests to disclose.

Author Contributions

All authors contributed to the study conception and design. Data collection and analysis were performed by YG, XL, JR, CZ, ZG. The first draft of the manuscript was written by YG and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guan, Y., Li, X., Li, H. et al. Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions. High Blood Press Cardiovasc Prev 30, 561–572 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: